Skip to main content

Table 1 Comparing surface ECG and Holter monitoring variables at baseline and after completion of treatment

From: Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring

Variable Baseline (n = 50) After completion of treatment (n = 50) p value
Surface ECG
PR interval, ms 154 ± 25.95 151.4 ± 23.82 0.124
QTc interval, ms 397.34 ± 29.38 395.04 ± 30.23 0.403
24-h ECG (Holter) monitoring
Minimum heart rate, bpm 55.88 ± 9.2 56.66 ± 9.45 0.457
Maximum heart rate, bpm 129.08 ± 20.07 128.98 ±16.89 0.964
Average heart rate, bpm 79.44 ±10.14 79.96 ± 8.77 0.534
Patients with significant pauses, n (%) 0 (0%) 0 (0%) 1
Patients with sinus tachycardia episodes, n (%) 47 (94%) 47 (94%) 1
Patients with sinus bradycardia episodes, n (%) 35 (70%) 33 (66%) 0.83
Patients with PACs, n (%) 6 (12%) 3 (6%) 0.485
Patients with PVCs, n (%) 22 (44%) 14 (28%) 0.145
  1. Continuous variables are expressed as mean and standard deviation, whereas categorical variables are expressed as number (percentage)
  2. QTc interval corrected QT interval, PACs premature atrial contraction, PVCs premature ventricular contractions